MORPHOLOGICAL CHARACTERISTICS AND CLINICAL VALUE OF DIFFERENT TYPES OF VESSELS INTO A TISSUE OF REGIONAL LYMPH NODES IN PATIENTS WITH GASTRIC CANCER

2015 ◽  
pp. 37
Author(s):  
Evgeniya Yu. Tishkova
Kanzo ◽  
2005 ◽  
Vol 46 (7) ◽  
pp. 437-442 ◽  
Author(s):  
Tadashi YOSHIDA ◽  
Atsushi NAGASAKA ◽  
Yayoi OGAWA ◽  
Syuji NISHIKAWA ◽  
Akifumi HIGUCHI

2018 ◽  
Vol 64 (3) ◽  
pp. 335-344
Author(s):  
Aleksey Karachun ◽  
Yuriy Pelipas ◽  
Oleg Tkachenko ◽  
D. Asadchaya

The concept of biopsy of sentinel lymph node as the first lymph node in the pathway of lymphogenous tumor spread has been actively discussed over the past decades and has already taken its rightful place in breast and melanoma surgery. The goal of this method is to exclude vain lymphadenectomy in patients without solid tumor metastases in regional lymph nodes. In the era of minimally invasive and organ-saving operations interventions it seems obvious an idea to introduce a biopsy of sentinel lymph node in surgery of early gastric cancer. Meanwhile the complexity of lymphatic system of the stomach and the presence of so-called skip metastases are factors limiting the introduction of a biopsy of sentinel lymph node in stomach cancer. This article presents a systematic analysis of biopsy technology of signaling lymph node as well as its safety and oncological adequacy. Based on literature data it seems to us that the special value of biopsy of sentinel lymph nodes in the future will be in the selection of personalized surgical tactics for stomach cancer.


2001 ◽  
Vol 36 (10) ◽  
pp. 710-717 ◽  
Author(s):  
Masayuki Nakamura ◽  
Eishi Mizuta ◽  
Hideshi Morioka ◽  
Mitsuo Nakamura ◽  
Kimio Isiglo

1992 ◽  
Vol 25 (10) ◽  
pp. 2520-2524 ◽  
Author(s):  
Hajime Abe ◽  
Nobukuni Terata ◽  
Hisanori Shiomi ◽  
Hiroyuki Naito ◽  
Junsuke Shibata ◽  
...  

1986 ◽  
Vol 19 (4) ◽  
pp. 840-843
Author(s):  
Jiro FUJIMOTO ◽  
Isao KOKUNAI ◽  
Tokuhiro MIYAMOTO ◽  
Satoshi TANE ◽  
Hitoshi SHIOZAKI ◽  
...  

2014 ◽  
Author(s):  
Mao Tokumoto ◽  
Hiroaki Tanaka ◽  
Masaichi Ohira ◽  
Yukie Go ◽  
Yoshihiro Okita ◽  
...  

Surgery Today ◽  
1999 ◽  
Vol 29 (6) ◽  
pp. 549-552 ◽  
Author(s):  
Hisayuki Shigematsu ◽  
Akira Kurita ◽  
Yasushi Omura ◽  
Yoshiro Kubo ◽  
Shigemitsu Takashima ◽  
...  

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 121-121
Author(s):  
Mai Tsutsui ◽  
Tsunehiro Takahashi ◽  
Yoshiro Saikawa ◽  
Hirofumi Kawakubo ◽  
Norihito Wada ◽  
...  

121 Background: Although the prognosis of early gastric cancer is favorable, the treatment for advanced cases still have difficulty in achieving satisfactory results. Thus, more effective multimodality treatment should be established. Chemoradiotherapy has become a standard treatment for gastric cancer especially as an adjuvant therapy while radiotherapy has been expected as one of the modalities against highly advanced gastric cancer. Methods: Patients with advanced gastric cancer who were treated with chemotherapy of S-1 and cisplatin plus radiation were analyzed retrospectively. Concurrent radiation therapy (5 days/week) at 2 Gy/day was started with chemotherapy and repeated daily on days 1–5, 8–12, 15–19 and 22–26. Irradiation was planned using a computed tomography (CT) simulator for two rectangular portals with a pair of 45-degree wedge filters and was targeted at the primary tumor and surrounding lesions, including lymph nodes. Results: A total 109 patients were treated with chemoradiotherapy between 2002 and 2013 at our institute. The median age was 64 years. Histological type included 45 differentiated and undifferentiated 64 subtypes. The TNM stage before the treatment was diagnosed as IIIA: 11; IIIB: 10; IIIC: 14; IV: 74. Of the 98 evaluable patients, 69 patients had partial responses while no patients had a complete response, resulting in an overall response rate of 70%. Progressive disease (PD) occurred in 2 patients (4%). The most frequent adverse events more than grade 3 were hematologic toxicities, including leukocytopenia (47%), neutropenia (25%), and thrombocytopenia (24%). Non-hematologic toxicities such as general fatigue, renal-related events, and gastrointestinal toxicities were manageable with no treatment-related death. The median survival time was 537 days. Conclusions: While there were disadvantages of radiotherapy including the difficulty of confirming the area of irradiation due to peristaltic movement, risk of perforation and ulceration, recent technological advancement of radiation therapy has enabled pinpoint accuracy in treatment of primary gastric lesions and regional lymph nodes. There has been much anticipation that chemoradiotherapy will be a part of multidisciplinary treatment for advanced cancer.


1994 ◽  
Vol 55 (9) ◽  
pp. 2310-2314
Author(s):  
Akihiko MIZOE ◽  
Kimiro TANAKA ◽  
Kazuhide URA ◽  
Tsutomu TOMIOKA ◽  
Kunihide IZAWA ◽  
...  

Author(s):  
Yoshiaki KITA ◽  
Futoshi MIYAZONO ◽  
Takahiko HAGIWARA ◽  
Tetsushi SAIHARA ◽  
Shoji NATSUGOE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document